Stock Events

Response Oncology 

$0
2
+$0+0% Tuesday 15:30

Statistics

Day High
0
Day Low
0
52W High
0
52W Low
0
Volume
1,700
Avg. Volume
1,700
Mkt Cap
1,218
P/E Ratio
0
Dividend Yield
-
Dividend
-

People Also Follow

This list is based on the watchlists of people on Stock Events who follow ROIX. It's not an investment recommendation.

Competitors

This list is an analysis based on recent market events. It's not an investment recommendation.
Vertex Pharmaceuticals
VRTX
Mkt Cap126.85B
Vertex Pharmaceuticals focuses on developing and commercializing therapies for cancer and other serious diseases, directly competing in the oncology market.
Bristol-Myers Squibb
BMY
Mkt Cap86.44B
Bristol-Myers Squibb is a major player in the oncology sector, developing numerous drugs for various types of cancer, overlapping with Response Oncology's market.
Merck &
MRK
Mkt Cap318.55B
Merck is known for its strong portfolio in cancer treatment, including immunotherapy drugs that compete in the same space as Response Oncology's offerings.
Pfizer
PFE
Mkt Cap169.83B
Pfizer has a broad range of cancer treatments, including therapies for breast and lung cancer, competing with Response Oncology's cancer care solutions.
Novartis
NVS
Mkt Cap232.42B
Novartis offers targeted cancer therapies and has a significant presence in the oncology market, making it a direct competitor.
AMGEN
AMGN
Mkt Cap177.72B
Amgen specializes in human therapeutics, including treatments for cancer, which pits it against Response Oncology in the oncology treatment market.
Gilead Sciences
GILD
Mkt Cap90.4B
Gilead Sciences, known for its innovations in medicine, also has a growing focus on oncology, competing with Response Oncology's cancer therapies.
Regeneron Pharmaceuticals
REGN
Mkt Cap114.81B
Regeneron Pharmaceuticals is involved in developing and commercializing products for treating cancer, directly competing with Response Oncology.
Astrazeneca
AZN
Mkt Cap244.04B
AstraZeneca has a strong pipeline in oncology, including therapies for various cancers, which competes with Response Oncology's products.
Johnson & Johnson
JNJ
Mkt Cap372.29B
Johnson & Johnson, through its pharmaceutical division, develops treatments for several types of cancer, competing in the same space as Response Oncology.

About

Medical/Nursing Services
Health Services
Health Care and Social Assistance
Offices of Physicians (except Mental Health Specialists)
Response Oncology, Inc. does not have significant operations. The company, along its wholly owned and majority owned subsidiaries, operated as a comprehensive cancer management company. As of May 20, 2002, the company has liquidated substantially all of its operating assets and anticipates that the remaining assets would be liquidated and all wind-down activities completed by the end of 2002. Prior to the sale of its assets, it provided: advanced cancer treatment services through outpatient facilities known as IMPACT Centers under the direction of practicing oncologists; owned the assets of and managed the nonmedical aspects of oncology practices; compounded and dispensed pharmaceuticals to certain oncologists for a fixed or cost plus fee; and conducted outcomes research on behalf of pharmaceutical manufacturers. The company was incorporated in 1984 and is based in Memphis, Tennessee.
Show more...
CEO
Employees
10
Country
US
ISIN
US7612323052

Listings